I share these words and this story with you because maybe, just maybe, today you needed to be told that you are bigger, better than you know. Maybe you needed someone to say, “I see you.” Maybe you needed to be reminded that your rough edges, your heartbreaking mess, holds within it staggering beauty. Please don’t hide, apologize, defer, shrink, or wait any longer. Shine (even if it feels scary and messy)… so that you can illuminate the world.
I’d like to share part of the map of a psychedelic journey that I’ve been sketching out over the past few years drawing from both personal experience and from my work as a psychotherapist and life coach. I’ll focus on three key points on this map: attachment issues, brain lateralization and meditation practice. We’ll see how connecting these points can reveal a promising path for healing our earliest and deepest wounds.
Although the ideal way to use ketamine likely entails receiving the treatment in a safe and comfortable setting, in an unrushed atmosphere, with a supportive psychotherapist or counselor nearby (or just a phone call away), this is not always the experience that the ever-growing number of ketamine treatment facilities offer their patients.
This is an introduction to a new guide for community-led peer integration circles, which will provide context and practical methods for setting up a peer circle, as well as critical considerations for how communities can effectively support themselves to meet their own integration needs. The guide is unique in that it takes an in-depth look
Article originally featured on Kahpi. Ryan was a meditator, experienced with ayahuasca, so it surprised him (not in a good way) when a disturbing ceremony revealed the world as hollow and grotesquely meaningless. In the aftermath, he felt dissociated and numb. It took him the better part of a year to recover, and he was
I’m not a medical doctor or therapist but a person who carries insights into how and why psychedelics hold such enormous therapeutic potential. Having personally experienced hallucinogens hundreds of times, primarily LSD and psilocybin, I’ve encountered the inner, transforming experience of reaching a state of mind that's powerfully self-illuminating. In the midst of a downward
The Food and Drug Administration (FDA) and the National Institutes of Health (NIH) communicated publicly about psychedelic drug development and current thinking around safety, therapeutic use, and research. The FDA Division of Psychiatry Products provided information in a workshop about how to design and efficiently study psychedelics for potential medical use.
Journaling can be an incredibly valuable tool in your ayahuasca integration process, and indeed in working with all psychedelics. The process of writing—not for an audience, strictly for yourself—clarifies thoughts and feelings, helping you recognize patterns that run through your life.
Six phase 2 trials investigated MDMA-assisted psychotherapy for treatment of PTSD. Results that led to Breakthrough Therapy designation are now published.
Psychedelic therapy holds a lot of promise, which medicine is right for you? Dr. Raquel Bennett describes her journey to find ketamine assisted psychotherapy and launch the first ketamine specific conference. She talks about different methods and approaches used in ketamine therapy. After struggling for over a decade with severe depression, Raquel Bennett turned to
In May 2017, the first psychedelic integration circle was hosted in Los Angeles with the purpose of creating a safe space for people to talk about non-ordinary states of consciousness and offer emotional support, educational information, and harm reduction strategies to individuals who use psychedelic substances. Nearly three years later, PsychedeLiA: Psychedelic Integration, Los Angeles’
Our site is about how to cultivate sacredness and silence in everyday life by becoming more aware of what’s obvious; not by searching for anything hidden or lost.
Until recently, the only opportunity to train and work legally as a psychedelic therapist was in clinical trials. That will likely change over time as expanded access becomes the next step for current trials (evaluating MDMA and psilocybin) and if psychedelic-assisted therapies become FDA approved.